Summary of Shandong Weigao Conference Call Company Overview - **Company**: Shandong Weigao (Ticker: 1066.HK) - **Industry**: China Healthcare - **Market Position**: - WEGO Prefills holds over 50% market share in pharma packaging in China, serving 700-800 domestic and 200+ international biopharma clients [2] - Weigao Blood Purification is the leading player in blood purification in China with over 30% market share, primarily serving hospitals' hemodialysis departments [2] Key Points Strategic Developments - **Synergies**: Post-integration of WEGO Prefills and Weigao Blood, the latter can leverage its filtration technology to develop upstream solutions for biopharma clients, targeting a Rmb21 billion market in China [2] - **Growth Strategy**: Weigao plans to enhance investment in perioperative and interventional device sectors, utilizing cash flow from its consumable business and considering M&A opportunities [3][8] Financial Outlook - **2025 Earnings Preview**: Expected low single-digit revenue growth and a slight decline in net profit, attributed to negative foreign exchange impacts [3] - **Valuation**: The deal valuation of Rmb8.5 billion suggests a profit multiple of 14.7x for 2024 and 13.3x for 2026, with a high single-digit organic CAGR for WEGO Prefills considered fair [8] Market Performance - **Stock Rating**: Equal-weight with a price target of HK$6.20, indicating a 19% upside from the current price of HK$5.23 [5] - **Market Capitalization**: Approximately HK$23.65 billion with an average daily trading value of HK$72 million [5] Risks and Considerations - **Upside Risks**: Better-than-expected core business performance, favorable government policies, successful product rollouts, and accretive M&A [13] - **Downside Risks**: Regulatory challenges, intense competition affecting growth and margins, and potential underperformance in orthopedics and interventional devices [13] Additional Insights - **Integration Impact**: The integration of WEGO Prefills and Weigao Blood is subject to minority shareholder approval and regulatory approvals, with Weigao expected to hold a 52.1% stake post-deal [8] - **Financial Metrics**: Projected EPS growth from Rmb0.45 in 2024 to Rmb0.49 in 2027, with revenue expected to rise from Rmb13.09 billion in 2024 to Rmb15.73 billion in 2027 [5] This summary encapsulates the strategic direction, financial outlook, and market positioning of Shandong Weigao, highlighting potential investment opportunities and risks within the healthcare sector in China.

Summary of Key Points Core Viewpoint - On January 6, 50 Hong Kong-listed companies conducted share buybacks, totaling 19.62 million shares and an aggregate amount of 861 million HKD [1]. Group 1: Major Companies Involved in Buybacks - Tencent Holdings repurchased 1.003 million shares for 636 million HKD, with a highest price of 638.000 HKD and a lowest price of 626.500 HKD, bringing its year-to-date buyback total to 1.907 billion HKD [1]. - Xiaomi Group-W repurchased 3.85 million shares for 150 million HKD, with a highest price of 38.900 HKD and a lowest price of 38.860 HKD, accumulating a year-to-date buyback total of 299 million HKD [1]. - Genscript Biotech repurchased 400,000 shares for 13.67 million HKD, with a highest price of 34.480 HKD and a lowest price of 33.840 HKD, totaling 27.25 million HKD in year-to-date buybacks [1]. Group 2: Buyback Amounts and Quantities - The highest buyback amount on January 6 was from Tencent Holdings at 636 million HKD, followed by Xiaomi Group-W at 150 million HKD [1]. - In terms of buyback quantity, Xiaomi Group-W led with 3.85 million shares, followed by Jieli Trading and Weigao Group with 2 million shares and 1.5948 million shares, respectively [1]. Group 3: Additional Companies and Their Buybacks - Weigao Group repurchased 1.5948 million shares for 8.22 million HKD, with a highest price of 5.230 HKD and a lowest price of 5.010 HKD [1]. - Geely Automobile repurchased 423,000 shares for 749.94 million HKD, with a highest price of 17.810 HKD and a lowest price of 17.570 HKD [1]. - Other notable companies include Tsugami Machine Tool, which repurchased 150,000 shares for 511.53 million HKD, and China National Chemical Corporation, which repurchased 150,000 shares for 446.94 million HKD [1].

威高股份回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2026.01.06 | 159.48 | 5.230 | 5.010 | 822.33 | （文章来源：证券时报网） 证券时报·数据宝统计，威高股份在港交所公告显示，1月6日以每股5.010港元至5.230港元的价格回购 159.48万股，回购金额达822.33万港元。该股当日收盘价5.230港元，下跌1.32%，全天成交额1.38亿港 元。（数据宝） ...

Core Viewpoint - Weigao Co., Ltd. is undergoing a significant restructuring by exchanging its subsidiary Weigao Purui for shares in Weigao Blood Purification, which will enhance its control and optimize asset allocation, aiming for long-term growth and strategic focus in the healthcare sector [1][2][3] Group 1: Transaction Details - The total transaction price for the asset swap is 8.511 billion yuan, with a price-to-earnings (PE) ratio of 14.66 times based on Weigao Purui's projected net profit for 2024 [1][2] - Weigao Co., Ltd. will increase its stake in Weigao Blood Purification from 23.5% to 52.0%, achieving controlling interest [1][2] - The share price for the new issuance is set at 31.29 yuan, which is approximately 20% lower than Weigao Blood Purification's market price of around 42 yuan at the time of the announcement, providing additional value to Weigao Co., Ltd. shareholders [2] Group 2: Market Position and Growth Potential - Weigao Blood Purification is a leading player in the blood purification market, with a comprehensive product line and sales to over 6,000 medical institutions in China, including more than 1,000 tertiary hospitals [3][4] - The number of hemodialysis patients in China is projected to reach 1.027 million by the end of 2024, reflecting a growth rate of 24%, indicating a robust market for blood purification treatments [4] - The global chronic kidney disease patient population is estimated at 788 million, with China having the highest number, suggesting a growing demand for blood purification services [3][4] Group 3: Strategic Implications - The restructuring is a critical step for Weigao Group to optimize its core assets and enhance its financial performance, including revenue and profit metrics [5] - The integration of Weigao Blood Purification will allow Weigao Co., Ltd. to strengthen its business segments, including single-use medical devices and orthopedic medical devices, creating a clearer operational structure [5] - The company aims to explore new growth opportunities in the biopharmaceutical upstream market, leveraging its existing technologies and market presence [6][7]

智通财经APP讯，威高股份(01066)发布公告，于2026年1月6日，该公司斥资822.33万港元回购159.48万 股。 ...

威高股份(01066)发布公告，于2026年1月6日，该公司斥资822.33万港元回购159.48万股。 ...

格隆汇1月6日丨威高股份(01066.HK)发布公告，2026年1月6日耗资822.33万港元回购159.48万股，回购 价格每股5.01-5.23港元。 ...

智通財經APP訊，威高股份(01066)發佈公告，於2026年1月6日，該公司斥資822.33萬港元回購159.48萬 股。 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2026年1月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...

Core Viewpoint - Weigao Blood Purification announced plans to acquire 100% equity of Weigao Purui for approximately 8.511 billion yuan through a share issuance, expanding its business into the development, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems [1] Group 1 - The transaction involves purchasing shares from three parties: Weigao Co., Weihai Shengxi, and Weihai Ruiming [1] - The share issuance price is set at 31.29 yuan per share [1] - Upon completion of the transaction, Weigao Purui will become a wholly-owned subsidiary of Weigao Blood Purification [1]